Clinical and Laboratory Investigation of Humans With Informative Iron or Erythroid Phenotypes
NCT ID: NCT00102245
Last Updated: 2018-02-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
334 participants
OBSERVATIONAL
2005-01-18
2017-08-04
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Patients of all ages with red cell abnormalities in the following categories may be eligible for this study:
* Diseases with deficiency, overload or maldistribution of iron
* Known red blood cell diseases, such as anemias and hemoglobinopathies
* Red blood cell diseases of unknown cause, such as hemolysis of unknown cause
* Red blood cell abnormalities with no overt clinical disease, such as hereditary persistence of fetal hemoglobin
Participants undergo the following procedures:
* Medical history
* Physical examination
* Standard medical tests related to the individual's iron or red blood cell condition
Blood draw for the following purposes:
* Testing for syphilis and for the hepatitis B and C, HIV, and HTLV-1viruses, and for a pregnancy test for women who can become pregnant
* Research purposes. This blood is analyzed for genes, proteins, sugars, and fat molecules.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Iron Depletion and Replacement in Blood Donors
NCT01752413
Iron Replacement in Blood Donors
NCT00327067
Relative Contributions of Red Cell Catabolism and Dietary Absorption to Fetal Iron Accretion During Pregnancy
NCT01588665
Low-dose Iron Supplementation and Markers of Iron Status Among Non-anemic, Iron-deficient Women
NCT02683369
Donor Iron Deficiency Study - Red Blood Cells From Iron-deficient Donors: Recovery and Storage Quality
NCT02889133
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
With the completion of the sequencing of the human genome, a more complete, genetically based description of disease is now achievable. Efforts aimed toward haplotype mapping will further enhance genotype phenotype correlation directly from clinical samples. Considerable progress has already been made in this regard using normal human erythroid cells. In contrast to classic studies involving single genes or proteins, computational biology and high throughput technologies permit the analysis of complex erythroid phenotypes including those with related iron pathologies. This information will be invaluable for understanding those molecular mechanisms that are altered in disease states.
The immediate aim of this protocol is to perform phenotypic analyses in humans with informative iron or erythroid phenotypes. These studies are expected to result in detailed clinical phenotyping and the collection and banking of clinical specimens for further study. In addition, we predict an ongoing growth of new technologies that may eventually be used for molecular and genetic phenotyping of clinical samples (examples include oligonucleotide chips and high throughput mass spectroscopy). Based upon this prediction, we plan to use the samples collected here to assess possible clinical uses of those technologies as they become available. The eventual aim is the discovery of identifiers that may be predictive of disease pathogenesis, severity or clinical response to intervention.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Group 1: Patients with known iron or erythroid diseases (examples: iron deficient anemia or ineffective erythropoiesis).
OR
Group 2: Patients with diseases of unknown etiology (example: unexplained iron overload or anemia).
OR
Group 3: Patients with an informative phenotype in the absence of overt clinical disease (example: hereditary persistence of fetal hemoglobin).
OR
Group 4: Healthy volunteers whose blood or bone marrow samples will be utilized to understand normal iron and erythroid biology and for comparison with the other groups described above.
AGE AND GENDER CONSIDERATIONS:
* Age range: Infancy to unlimited
* Adults: Adults who fall into Groups 1-4 are eligible to enroll in this protocol. They must possess the ability to comprehend the investigational nature of the study and provide informed consent.
* Minors: Minors who fall into groups 1-4 are eligible to enroll in the study for collection of research blood. Within Group 4 (healthy volunteers, minors), the research will not involve greater than minimal risk.
Exclusion Criteria
1 Year
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jeffery L Miller, M.D.
Role: PRINCIPAL_INVESTIGATOR
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Goh SH, Josleyn M, Lee YT, Danner RL, Gherman RB, Cam MC, Miller JL. The human reticulocyte transcriptome. Physiol Genomics. 2007 Jul 18;30(2):172-8. doi: 10.1152/physiolgenomics.00247.2006. Epub 2007 Apr 3.
Gubin AN, Njoroge JM, Wojda U, Pack SD, Rios M, Reid ME, Miller JL. Identification of the dombrock blood group glycoprotein as a polymorphic member of the ADP-ribosyltransferase gene family. Blood. 2000 Oct 1;96(7):2621-7.
Gubin AN, Njoroge JM, Bouffard GG, Miller JL. Gene expression in proliferating human erythroid cells. Genomics. 1999 Jul 15;59(2):168-77. doi: 10.1006/geno.1999.5855.
Miller JL. Signaled expression of fetal hemoglobin during development. Transfusion. 2005 Jul;45(7):1229-32. doi: 10.1111/j.1537-2995.2005.00182.x. No abstract available.
Goh SH, Lee YT, Bhanu NV, Cam MC, Desper R, Martin BM, Moharram R, Gherman RB, Miller JL. A newly discovered human alpha-globin gene. Blood. 2005 Aug 15;106(4):1466-72. doi: 10.1182/blood-2005-03-0948. Epub 2005 Apr 26.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
05-DK-0085
Identifier Type: -
Identifier Source: secondary_id
050085
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.